Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin

Inclusion Criteria:

1. Men and women of any ethnic origin aged between 18 and 49 years of age, inclusive,at the time of Screening.

2. Male subjects must be willing to use appropriate contraception, such as a condom,and to refrain from sperm donation during the main study and until 90 days afterstudy drug administration.

3. Women of child-bearing potential must agree not to attempt to become pregnant and touse a highly effective form of birth control during the main study and for 90 daysafter study drug administration when their sexual partner has not been vasectomized.Highly effective forms of birth control entail the use of combined (estrogen- andprogestogen-containing) or progestogen-only hormonal contraception associated withinhibition of ovulation, an intrauterine device (IUD), an intrauterinehormone-releasing system (IUS) or abstinence.

4. Postmenopausal women must have had ≥12 months of spontaneous amenorrhea (withdocumented follicle stimulating hormone [FSH] >33.4 IU/L).

5. Surgically sterile women are defined as those who have had a surgical bilateraloophorectomy with or without hysterectomy, total hysterectomy or tubal ligation atleast six weeks before taking study treatment. In case of oophorectomy alone, thereproductive status of the woman has to be confirmed by follow-up hormone levelassessment. Women who are surgically sterile must provide documentation of theprocedure by an operative report or by ultrasound.

6. Subject must weigh between 60 and 120 kg, inclusive, and must have a BMI between 18.0 and 30.0 kg/m2, inclusive, at Screening and on Day -1.

7. Subject must be in good health, as determined by a medical history, physicalexamination, 12-lead ECG and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia is acceptable).

8. Subject is willing and able to give their written informed consent to participate inthe study and to abide by the study restrictions.

9. Subject has good upper limb venous access.

Exclusion Criteria:

1. The subject has taken tenoxicam in the 35 days prior to Day 1 or has taken piroxicamin the two weeks prior to Day 1.

2. The subject is receiving or requires, for any cause, any anticoagulant orantiplatelet therapy including warfarin, clopidogrel or aspirin or any otheranticoagulant or antiplatelet agent or has used these therapies in the 4 weeks priorto Day 1.

3. The subject has taken any non-aspirin, non-tenoxicam, non-piroxicam non-steroidalantiinflammatory drug (NSAID) in the week prior to Day 1.

4. The subject requires or has taken during the 4 weeks prior to Day 1, vitamin K fortherapeutic reasons. Vitamin K not taken for therapeutic purposes is acceptable,e.g. as part of a multivitamin supplement.

5. The subject has received any prescribed oral, systemic or topical medication,including any vaccinations, within 14 days before Day 1 (with the exception ofcontraceptives), unless in the opinion of the Principal Investigator and the MedicalMonitor the medication will not interfere with the study procedures or compromisesafety.

6. The subject has used any non-prescribed systemic or topical medication (includingherbal remedies) within 4 days prior to Day 1 (with the exception of oralvitamin/mineral supplements [including those that contain vitamin K when not takenfor therapeutic purposes] and paracetamol), unless in the opinion of the PrincipalInvestigator and the Medical Monitor the medication will not interfere with thestudy procedures or compromise safety.

7. The subject has been administered an investigational drug (new chemical orbiological entity) within 4 weeks prior to Day 1 for small molecules or within 12weeks or 5 halflives, whichever is longer, prior to Day 1 for all other types ofinvestigational drug.

8. The subject has donated ≥500 mL blood, plasma or platelets in the 12 weeks prior toScreening or the subject has donated any blood amount within 30 days prior toScreening.

9. Because of an increased risk of thrombosis, subjects with known diabetes mellitus ora fasted glucose ≥7.0 mmol/l at Screening.

10. The subject has any bleeding diathesis, any increased risk of bleeding or, in theopinion of the Principal Investigator, is at increased risk of the consequences ofbleeding including but not limited to the following:

11. gastro-intestinal ulceration within the last 12 weeks;

12. known or suspected oesophageal varices;

13. vascular aneurysms or known arteriovenous malformations;

14. history of known major intraspinal or intracerebral vascular abnormalities;

15. history of brain, spinal or ophthalmic surgery within the last year;

16. any intracranial hemorrhage;

17. uncontrolled severe hypertension.

18. The subject has, in the opinion of the Principal Investigator, any increased risk ofthrombosis or thromboembolism including any known thrombophilia, such asantiphospholipid syndrome, or any past history of provoked or unprovoked arterial orvenous thrombosis, including thromboembolism.

19. The subject has a significant history of drug allergy, as determined by thePrincipal Investigator.

20. The subject has, at Screening or on Day -1, a supine blood pressure or supine pulserate ≥ 150/95 mmHg and >100 beats per minute (bpm), respectively, or < 90/40 mmHgand 40 bpm, respectively, confirmed by a repeat assessment.

21. The subject consumes > 21 alcoholic drinks/week for men or > 14 alcoholicdrinks/week for women (one unit of alcohol equals ½ pint [285 mL] of beer or lager,one glass [125 mL] of wine, or 1 measure [25 mL] of spirits), or has a significanthistory of alcoholism or drug/chemical abuse, as determined by the PrincipalInvestigator.

22. The subject has a positive drug screen, alcohol test or cotinine test result atScreening or on Day -1, confirmed by repeat testing.

23. The female subject has a positive pregnancy test at Screening or on Day -1, or islactating.

24. The subject currently smokes or uses nicotine-containing products. Former smokerswill be eligible, provided they have not smoked for at least 4 weeks prior toadministration of the study drug.

25. The subject has, or has a history of, any clinically significant neurological,gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory,metabolic, endocrine, hematological or other major disorders, as determined by thePrincipal Investigator.

26. The subject has a positive Hepatitis B surface antigen (HBsAg), Hepatitis Cantibody, or human immunodeficiency virus (HIV) antibody test result at Screening.

27. The subject has an abnormality in the 12-lead ECG at Screening or on Day -1 that, inthe judgement of the Principal Investigator may, during the main study, interferewith the interpretation of 12-lead ECG results, including average QTcF interval >450msec for men or >470 msec for women, 2nd or 3rd degree atrioventricular block,complete left bundle branch block, complete right bundle branch block orWolff-Parkinson-White Syndrome, defined as average PR<110 msec, confirmed by atriplicate repeat ECG.

28. The subject has any other condition that, in the opinion of the PrincipalInvestigator, would compromise the safety of the subject or the subject's ability tocomply with the protocol and complete the study.

29. The subject has renal insufficiency (serum creatinine level > 1.25 times upper limitof normal (ULN) or estimated glomerular filtration rate (eGFR) of <60mL/minute*1.73m2 at Screening or on Day -1. One re-test is allowed).

30. The subject has active liver disease (alanine transaminase [ALT]/ aspartatetransaminase [AST] >1.5x ULN, or total bilirubin > 1.5x ULN at Screening or on Day -1. One re-test is allowed).

31. The subject has previously participated in a clinical study with VMX-C001.

32. The subject has any contra-indication to treatment with heparin (LMWH or UFH). Additional exclusion criteria for UFH Cohort only:

33. Because of an effect on FXa DOACs, subjects are to be excluded if he/she receives orhas received medication that is an inhibitor of P-glycoprotein or CYP3A4. (egclarithromycin, erythromycin and azole-antimycotics such as ketoconazole,itraconazole, voriconazole and posaconazole or HIV protease inhibitors.) within 30days prior to Day 1.

34. Because of an effect on FXa DOACs, subjects are to be excluded if he/she receives orhas received treatment with CYP3A4 inducers (eg St. John's wort, rifampicin,phenytoin, carbamazepine, phenobarbital within 30 days prior to Day 1.

35. Because of an effect on FXa DOACs, subjects are to be excluded if he/she receives orhas received treatment with selective serotonin reuptake inhibitors (SSRIs) orselective noradrenaline reuptake inhibitors (SNRIs) within 30 days prior to Day 1.

36. The subject has any contra-indication to treatment with DOACs.